Gilead Sciences holds the cleaner structural position, with the lead spread across valuation and profitability. Eli Lilly and Company still has the edge on profitability, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
The lead is spread across valuation and stability, rather than sitting in one isolated gap. The overall score gap is 9 points in favour of Gilead Sciences, Inc..
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. GILD and LLY share the same industry classification.
For a similarity-based comparison, see how Gilead Sciences and Eli Lilly and Company each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
The two profiles are relatively close, but the price setup still leans toward Gilead Sciences, Inc..
Valuation position uses Forward P/E and peer-relative PE percentile (idx_pct_pe) where available.
Where GILD and LLY each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a forward P/E that is 10.9 turns lower.
Profitability still favours Eli Lilly and Company, with a 20.5-point operating margin advantage keeping the comparison from looking fully resolved.
The valuation edge is decisive, even though current pricing and profitability still lean somewhat toward Eli Lilly and Company.
Break down the GILD vs LLY comparison across all dimensions with the full interactive tool.
Explore how GILD and LLY each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.